We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multiparameter Immunochromatographic Assay Detects and Differentiates Hepatitis C Antibodies

By LabMedica International staff writers
Posted on 14 Aug 2013
A hepatitis C (HCV) rapid test has been developed that should provide additional information about the infection profile.

The Multisure HCV antibody assay is a qualitative, multiparameter, immunochromatographic assay, intended for the detection and differentiation of Hepatitis C antibodies that may be present in patients with acute or chronic Hepatitis C infection. The test was developed based on the patented reverse-flow technology, giving greater sensitivity and stronger visual signals.

Developed by MP Diagnostic (Solon, OH, USA), the Multisure HCV antibody assay uses human whole blood, plasma, or serum. It has a short test-time and can detect and differentiate HCV antibodies against both structural and non-structural proteins across all six genotypes. The assay is instrument free, easy to use, and is suitable for use at Point-of-Care (POC) or with automation. It does not require highly trained personnel to perform the test. It has shown excellent correlation with polymerase chain reaction (PCR), enzyme immunoassay (EIA), and Immunoblot.

MP Biomedicals received the CE marking for its new, multiparameter Hepatitis C test.

Related Links:

MP Diagnostic



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Amoebiasis Test
ELI.H.A Amoeba

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions